Apparatus and methods for delivery of therapeutic agents to mucous or serous membrane

Patent metadata

Field	Value
Publication number	US-10137247-B2
Application number	US-201514611708-A
Country	US
Kind code	B2
Filing date	Feb 2, 2015
Priority date	May 26, 2011
Publication date	Nov 27, 2018
Grant date	Nov 27, 2018

Abstract

A method, apparatus, and system are provided for mucous membrane therapy. The method includes receiving at least one body signal from a patient; detecting a condition of the patient based on the body signal; and administering the therapy to at least one of a mucous membrane or a serous membrane of the patient. A medical device system configured to implement the method is provided. A computer-readable storage device for storing instructions that, when executed by a processor, perform the method is also provided.

First claim

What is claimed is:

1. A method, comprising:
receiving from a sensor at least one body signal from a patient;
detecting a condition of said patient based on said body signal, said detecting a condition being detected by a therapy device; and
administering a therapy with said therapy device to at least one of a mucous membrane or a serous membrane of said patient, in response to said detecting; wherein said body signal is a signal indicative of a concentration of a therapeutic medication in a body fluid; said condition is said concentration of said therapeutic medication being above a second concentration; and said therapy comprises at least one of reducing a dose of said therapeutic medication, reducing a rate of delivery of said therapeutic medication, or delaying a delivery of said therapeutic medication.

2. The method of claim 1 , wherein said condition is a neurological or a psychiatric condition.

3. The method of claim 2 , wherein said neurological condition is epilepsy, headache, or a movement disorder.

4. The method of claim 3 , wherein said neurological condition is epilepsy; and said body signal is at least one of a cardiac signal, a respiration signal, a body movement signal, a skin resistance signal, a responsiveness signal, or an awareness signal.

5. The method of claim 4 , further comprising delivering an electrical stimulation therapy to a cranial nerve of said patient.

6. The method of claim 2 , wherein said therapy is a medicament, said medicament is selected from a benzodiazepine, a barbiturate, a CNS depressant drug, an anti-seizure drug, a local anesthetic, a vasoactive agent, an anti-inflammatory drug, a non-narcotic analgesic, a narcotic analgesic, a medicinal gas, or two or more thereof, wherein the medicament is delivered in an absorbable or inhalable form.

7. The method of claim 3 , wherein said neurological condition is migraine; and said body signal is a skin resistance signal.

8. The method of claim 3 , wherein said neurological condition is a movement disorder; and said body signal is a body movement signal.

9. The method of claim 1 , wherein said condition is a non-neurological condition.

10. The method of claim 9 , wherein said non-neurological condition is asthma, COPD, a cardiac disorder, vasodepressive syncope, or diabetes.

11. The method of claim 10 , wherein said non-neurological condition is at least one of asthma or COPD; and said body signal is at least one of a blood oxygen saturation signal, a lung sounds signal, a ratio of the inspiratory slope over the expiratory slope, a chest wall motion signal, an abdominal wall motion signal; and said mucous membrane is a nasal mucous membrane, an oral mucous membrane or a lung mucous membrane.

12. The method of claim 11 , wherein said therapy is a medicament selected from a bronchodilator, an anti-inflammatory drug, or oxygen, and wherein said medicament is absorbable or inhalable.

13. The method of claim 1 , wherein said body signal is a signal indicative of a concentration of a therapeutic medication in a body fluid; said condition is said concentration of said therapeutic medication being below a first concentration; and said therapy is a supplemental dosage of said therapeutic medication sufficient to raise said blood concentration of said therapeutic medication above said first concentration.

14. The method of claim 1 , wherein administering said therapy comprises delivering a medication in at least one of an aerosol formulation, a gas formulation, a liquid formulation, or a controlled release gel formulation.

15. The method of claim 1 , further comprising determining at least one therapy for said condition; and wherein said administering is of said at least one determined therapy.

16. A medical device system, comprising:
at least one sensor configured to sense at least one body signal from a patient;
a detection unit configured to receive at least one body signal from said sensor and detect a condition based on at least said body signal, wherein said condition is epilepsy; and
a therapy device configured to receive an indication of a detected condition from said detection unit and administer a therapy to at least one of a mucous membrane or a serous membrane of said patient, wherein said therapy device is configured for permanent attachment to an anatomical structure in proximity to at least one of said mucous membrane or said serous membrane;
wherein said body signal is a signal indicative of a concentration of a therapeutic medication in a body fluid; said condition is said concentration of said therapeutic medication being below a first concentration; and said therapy is a supplemental dosage of said therapeutic medication sufficient to raise a blood concentration of said therapeutic medication above said first concentration.

17. The medical device system of claim 16 , wherein said sensor is configured to receive at least one of a cardiac signal, a respiration signal, a body movement signal, a skin resistance signal, a responsiveness signal, or an awareness signal.

18. The medical device system of claim 16 , wherein said therapy device is configured for non-implantable coupling to an anatomical structure in proximity to at least one of said mucous membrane or said serous membrane.

19. The medical device system of claim 16 , wherein said therapy is a medication, and said therapy device is configured to administer an aerosol formulation of said therapy, a gas formulation of said therapy, a liquid formulation of said therapy, or a controlled release gel formulation of said therapy.

20. The medical device system of claim 16 , wherein said therapy device is configured to administer said therapy to a mucous membrane of the nose of said patient, and said therapy device is further configured to deliver an electrical stimulation therapy to a cranial nerve of said patient.

21. The medical device system of claim 16 , wherein said therapy device comprises a nozzle to deliver a therapy to said mucous membrane.

22. The medical device system of claim 16 , further comprising: a membrane therapy unit configured to determine at least one therapy for said condition, and wherein said therapy unit is configured to administer said at least one therapy determined by said membrane therapy unit.

23. The medical device system of claim 16 , further comprising a logging device configured to log one or more of the condition detected, the date and time of detection, the severity of the condition, the type(s) of therapy(ies) delivered, the site(s) of delivery of the therapy(ies), the dose of the therapy(ies), the level of efficacy of the therapy(ies), the level of tolerance of the therapy(ies), and the presence or absence of adverse effects of the therapy(ies).

24. A computer-readable storage device for storing instructions that, when executed by a processor, perform a method, comprising: detecting a condition requiring a therapy, based on at least one body signal sensed from a patient; and delivering a therapy to at least one of a mucous membrane or a serous membrane of said patient, wherein said body signal is a signal indicative of a concentration of a therapeutic medication in a body fluid; said condition is said concentration of said therapeutic medication being below a first concentration; and said therapy is a supplemental dosage of said therapeutic medication sufficient to raise a blood concentration of said therapeutic medication above said first concentration.

Assignees

• Osorio Ivan

Inventors

• Osorio Ivan

Classifications

• A61M2230/432

  partial CO2 pressure (P-CO2) · CPC title

• A61N1/0548

  Oral electrodes · CPC title

• A61M2230/60

  Muscle strain, i.e. measured on the user · CPC title

• A61M2202/0413

  Blood · CPC title

• A61M2205/3523

  using telemetric means · CPC title